Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio Key International (BKYI) Current Deferred Revenue (2017 - 2025)

Bio Key International (BKYI) has disclosed Current Deferred Revenue for 13 consecutive years, with $659627.0 as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue fell 8.37% to $659627.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $659627.0 through Sep 2025, down 8.37% year-over-year, with the annual reading at $773267.0 for FY2024, 50.15% up from the prior year.
  • Current Deferred Revenue hit $659627.0 in Q3 2025 for Bio Key International, down from $873394.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.1 million in Q1 2025 to a low of $462418.0 in Q4 2022.
  • Historically, Current Deferred Revenue has averaged $704595.5 across 5 years, with a median of $659627.0 in 2025.
  • Biggest five-year swings in Current Deferred Revenue: decreased 26.95% in 2022 and later soared 50.15% in 2024.
  • Year by year, Current Deferred Revenue stood at $633000.0 in 2021, then fell by 26.95% to $462418.0 in 2022, then rose by 11.37% to $515000.0 in 2023, then skyrocketed by 50.15% to $773267.0 in 2024, then fell by 14.7% to $659627.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for BKYI at $659627.0 in Q3 2025, $873394.0 in Q2 2025, and $1.1 million in Q1 2025.